Precision BioSciences IPO
Precision BioSciences is a clinical-stage biotechnology company developing gene editing therapies using its proprietary ARCUS platform. The company focuses on both in vivo and allogeneic cell therapy applications for treating genetic disorders and cancer. Investors monitor Precision's clinical progress and the competitive gene editing landscape.
Key Facts
| Industry | Gene Editing Biotechnology |
| Founded | 2006 |
| Headquarters | Durham, NC |
| Employees | ~200 |
| Website | precisionbiosciences.com |
| Funding | Public company (NASDAQ: DTIL) |
About Precision BioSciences
Precision BioSciences is a clinical-stage gene editing company that has developed a proprietary ARCUS genome editing platform based on engineered meganucleases. Unlike CRISPR-based approaches, ARCUS uses programmable nucleases that can be designed to target specific DNA sequences with high precision, potentially reducing off-target effects that have been a concern with other gene editing technologies. The company's platform is being applied to develop both in vivo gene therapies for inherited diseases and allogeneic CAR-T cell therapies for cancer treatment.
The company's lead programs include treatments for primary immunodeficiency diseases and various blood cancers, with several candidates in clinical trials. Precision BioSciences has also established partnerships with major pharmaceutical companies to apply their ARCUS technology to additional therapeutic areas. Their approach to gene editing represents an alternative to CRISPR technology, and their progress in clinical trials will be important for validating the commercial potential of meganuclease-based gene editing as a therapeutic modality.
IPO Status
Precision BioSciences went public in 2019 through a traditional IPO on NASDAQ under ticker DTIL. The company raised capital to advance its ARCUS gene editing platform and clinical programs. Like many clinical-stage biotech stocks, Precision has experienced significant volatility based on clinical trial updates, partnership announcements, and broader biotech market sentiment. Since its IPO, Precision has continued to develop its pipeline of gene editing therapies while also pursuing partnerships and collaborations. The company has advanced multiple programs through clinical trials and continues to expand applications of its ARCUS technology platform.
Competitors
Frequently Asked Questions
Does Precision BioSciences have a stock?
Yes, Precision BioSciences completed its IPO in 2019 and has been publicly traded since then. The company went public to fund its gene editing programs.
When is the Precision BioSciences IPO date?
Precision BioSciences already went public in 2019, so there is no upcoming IPO. The company has been trading publicly for several years.
How can I buy Precision BioSciences stock?
You can buy Precision BioSciences stock through any brokerage account under ticker DTIL. The company trades on NASDAQ and is available to investors.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts